S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
These biotechs targeting multiple neurodegenerative diseases
Earnings propel Crowdstrike, cybersecurity sector, to new highs
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
These biotechs targeting multiple neurodegenerative diseases
Earnings propel Crowdstrike, cybersecurity sector, to new highs
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
These biotechs targeting multiple neurodegenerative diseases
Earnings propel Crowdstrike, cybersecurity sector, to new highs
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
These biotechs targeting multiple neurodegenerative diseases
Earnings propel Crowdstrike, cybersecurity sector, to new highs

OKYO Pharma Stock Price, News & Analysis (NASDAQ:OKYO)

$1.66
+0.04 (+2.46%)
(As of 12/1/2023 ET)
Compare
Today's Range
$1.63
$1.73
50-Day Range
$1.57
$2.75
52-Week Range
$0.92
$7.00
Volume
4,798 shs
Average Volume
26,443 shs
Market Capitalization
$48.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

OKYO Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
140.2% Upside
$4.00 Price Target
Short Interest
Healthy
0.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$25,005 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

432nd out of 954 stocks

Biotechnology Industry

11th out of 24 stocks


OKYO stock logo

About OKYO Pharma Stock (NASDAQ:OKYO)

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

OKYO Stock Price History

OKYO Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
OKYO Pharma announces share offering
OKYO Pharma Announces Public Offering of Ordinary Shares
Okyo Pharma Ltd.
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Why Is OKYO Pharma (OKYO) Stock Down 19% Today?
OKYO Pharma ready to kick off dry eye trial in the US
See More Headlines
Receive OKYO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OKYO Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
12/02/2023
Next Earnings (Estimated)
12/28/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OKYO
Fax
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+140.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.08) per share

Miscellaneous

Free Float
17,167,000
Market Cap
$48.00 million
Optionable
Not Optionable
Beta
0.05
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Gary S. Jacob Ph.D. (Age 76)
    CEO & Executive Director
    Comp: $650k
  • Mr. Michael Paul Beck (Age 66)
    Founder
  • Ms. Keeren Shah (Age 46)
    Chief Financial Officer
  • Dr. William A. Clementi Ph.D.
    Pharm.D., Chief Operating Officer
  • Dr. Rajkumar Patil Ph.D. (Age 64)
    Chief Scientific Officer














OKYO Stock Analysis - Frequently Asked Questions

Should I buy or sell OKYO Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OKYO Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" OKYO shares.
View OKYO analyst ratings
or view top-rated stocks.

What is OKYO Pharma's stock price target for 2024?

1 brokers have issued 1-year target prices for OKYO Pharma's stock. Their OKYO share price targets range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 140.2% from the stock's current price.
View analysts price targets for OKYO
or view top-rated stocks among Wall Street analysts.

How have OKYO shares performed in 2023?

OKYO Pharma's stock was trading at $1.91 on January 1st, 2023. Since then, OKYO shares have decreased by 12.8% and is now trading at $1.6650.
View the best growth stocks for 2023 here
.

When is OKYO Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, December 28th 2023.
View our OKYO earnings forecast
.

When did OKYO Pharma IPO?

(OKYO) raised $2 million in an initial public offering on Tuesday, May 17th 2022. The company issued 625,000 shares at a price of $4.00 per share.

Who are OKYO Pharma's major shareholders?

OKYO Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Barclays PLC (0.09%).
View institutional ownership trends
.

How do I buy shares of OKYO Pharma?

Shares of OKYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:OKYO) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -